The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNI		on, D.C. 20549 ORM D		OMB APPROVALOMB 3235- Number: 0076Estimated average burdenhours per response: 4.00
1. Issuer's Identity				
CIK (Filer ID Nu	mber) Previous Names	X None		Entity Type
0001649989			X Corporatio	n
Name of Issue	er		Limited Pa	rtnership
Oncobiologics, Inc.			Limited Li	ability Company
Jurisdiction o Incorporation/Orga			General Pa	1
NEW JERSEY	IIIZAUOII		Business T	
	tion/Organization		Other (Spe	city)
Over Five Years Ago				
X Within Last Five Years (S Yet to Be Formed	Specify Year) 2011			
2. Principal Place of Busines	ss and Contact Information			
Name	of Issuer			
Oncobiologics, Inc.				
	Address 1		Street Address 2	
7 CLARKE DRIVE				
City	State/Province/Country			iber of Issuer
CRANBURY	NEW JERSEY	08512	6096193990	
3. Related Persons				
Last Name	Fir	st Name	Middle Na	me
Mohan	Pankaj			
Street Address 1	Street	Address 2		
c/o Oncobiologics, 7 Clarke				
City		vince/Country	ZIP/PostalC	Code
CRANBURY	NEW JERSEY		08512	
Relationship: X Executive	Officer X Director Promo	ter		
Clarification of Response (if	Necessary):			
Last Name	Fir	st Name	Middle Na	me
Griffith	Donald			
Street Address 1		Address 2		
c/o Oncobiologics, 7 Clarke				
City		vince/Country	ZIP/PostalC	Code
CRANBURY	NEW JERSEY		08512	

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Canute	Scott	
Street Address 1	Street Address 2	
c/o Oncobiologics, 7 Clarke Drive		
City	State/Province/Country	ZIP/PostalCode
CRANBURY	NEW JERSEY	08512
Relationship: Executive Officer	X Director Promoter	
Clarification of Response (if Necess	ary): First Name	Middle Name
Brady	Todd	
Street Address 1	Street Address 2	
c/o Oncobiologics, 7 Clarke Drive		
	State/Duorin co/Country	ZIP/PostalCode
City	State/Province/Country	
City CRANBURY	NEW JERSEY	08512
U	NEW JERSEY	

4. Industry Group

Electric Utilities

Oil & Gas

5. Issuer Size

Other Energy

Energy Conservation Environmental Services

Agriculture Banking & Financi Commercial Ban Insurance Investing Investment Bank Pooled Investment Is the issuer regis an investment co the Investment C	king ing nt Fund stered as mpany under	Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports
Act of 1940? Yes	No	Construction	Lodging & Conventions Tourism & Travel Services
	Financial Services	REITS & Finance	Other Travel
Business Services		Residential	X Other
Energy Coal Mining		Other Real Estate	

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000

X Decline to Disclose	Decline to Disclose
Not Applicable	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment C	Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)((2) Section 3(c)(10)	
Rule 504 (b)(1)(iii)	Section 3(c)((3) Section 3(c)(11)	
Rule 505	Section 3(c)((4) Section 3(c)(12)	
X Rule 506(b) Rule 506(c)	Section 3(c)((5) Section 3(c)(13)	
Securities Act Section 4(a)(5)	Section 3(c)(
	Section 3(c)(2	7)	
7. Type of Filing			
X New Notice Date of First Sale 2015-06-05 First Sale Yet to Occur Amendment			
8. Duration of Offering			
Does the Issuer intend this offering to last more th	an one year?	Yes X No	
9. Type(s) of Securities Offered (select all that app	y)		
X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)	

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

States

Recipient		Recipient CRD Number None	
Citi Group Global Markets, Inc.		7059	
(Associated) Broker or Dealer X None		(Associated) Broker or Dealer CRD Number	X None
None		None	
Street Address 1		Street Address 2	
388 Greenwich Street		32nd Floor	
City		State/Province/Country	ZIP/Postal Code
New York		NEW YORK	10013
State(s) of Solicitation (select all that apply) Check "All States" or check individual X A	All States	Foreign/non-US	

Recipient		Recipient CRD Number	None		
Jefferies LLC		2347			
(Associated) Broker or Dealer X None		(Associated) Broker or De Number	ealer CRD	X None	
None		None			
Street Address 1		Street A	Address 2		
520 Madison Avenue					
City		State/Province/Country		ZIP/Postal Code	ć
New York		NEW YORK		10022	
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	X All States	Foreign/non-US			
13. Offering and Sales Amounts					_

Total Offering Amount	\$31,050,000 USD or	Indefinite
Total Amount Sold	\$31,050,000 USD	
Total Remaining to be Sold	\$0 USD or	Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$1,200,000 USD	X Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or

pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Oncobiologics, Inc.	/s/ Pankaj Mohan	Pankaj Mohan	Chief Executive Officer	2015-08-10

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.